Comparative Pharmacology
Head-to-head clinical analysis: THIOTEPA versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOTEPA versus TREANDA.
THIOTEPA vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Deslanoside
"Thiotepa may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThiotepa + Acetyldigitoxin
"Thiotepa may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent